LITESPARK-012
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
- NCT04736706 ↗
- Active, not recruiting
- Merck Sharp & Dohme LLC
- Deep
We haven't built an HCP commentary report on LITESPARK-012 (pembrolizumab, belzutifan and 2 more in Carcinoma, Renal Cell) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LITESPARK-012 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 73 | |
| Podcasts | 6 | |
| YouTube | 3 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Pembrolizumab; Belzutifan; Pembrolizumab/Quavonlimab; Lenvatinib
- Arms
- Pembrolizumab + Belzutifan + Lenvatinib · Experimental
- Pembrolizumab/Quavonlimab + Lenvatinib · Experimental
- Pembrolizumab + Lenvatinib · Active comparator
- Enrollment
- 1,688
- Primary outcomes
- Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC with Eisai Inc.
- Start
- Apr 14, 2021
- Primary completion
- Feb 4, 2026
- Results posted
- No
- Registry record
- NCT04736706 · updated Oct 2, 2026
Publications
linked from the registry- Choueiri TK, Powles T, Voss MH, Plimack ER, Gurney H, Song Y, Perini RF, Rodriguez-Lopez K, Rini BI. LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma. Future Oncol. 2023 Dec;19(40):2631-2640. doi: 10.2217/fon-2023-0283. Epub 2023 Oct 26. PubMed 37882432
- Ged Y, Markowski MC, Singla N, Rowe SP. The shifting treatment paradigm of metastatic renal cell carcinoma. Nat Rev Urol. 2022 Nov;19(11):631-632. doi: 10.1038/s41585-022-00651-9. PubMed 36064785